EGFR-positive Colorectal CancerPhase 1/2NCT03152435
EGFR CART Cells for Patients With Metastatic Colorectal Cancer
A Phase 1/2 study testing EGFR CART in people with EGFR-positive Colorectal Cancer, run by Shenzhen Second People's Hospital at 1 site in China.
Trial summary
This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor EGFR (EGFR CART) cells in metastatic patients with colorectal cancer. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- EGFR-positive Colorectal Cancer
- What is being tested?
- EGFR CART
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteChina
- Study dates
- 15 Jun 2017to Dec 2019
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 1. Patients must be 18 years to 70 years;
- 2. Clinical diagnosis of EGFR positive for patients with metastatic colorectal cancer;
- 3. Patients must have a KPS of >80, expected survival > 3 months;
- 4. Patients must have at least one measurable lesions;
- 5. Recently did not use glucocorticoid;
- 6. Patients must have evidence of adequate hepatic and renal function as evidenced by the following laboratory parameters: WBC ≥ 4.0×109/L, Hb ≥90 g/L, PLT ≥100×109/L）; AST ≤2.5ULN，ALT ≤ 2.5ULN; Cr≤ 3ULN; TBIL≤ 3ULN，
Show all 9Show fewer
- 7. Patients must have a good heart function (LVEF>50%) ;
- 8. Patients must be willing to practice birth control during and for three months following treatment.NOTE:female participants of reproductive potential must have a negative serum pregnancy test, and willing to practice birth control during and for three months following treatment；
- 9. Patients must be willing to sign an informed consent.
Who cannot join
- 1. Patients with other cancer history;
- 2. Patients allergic to cetuximab;
- 3. Patients with severe bronchitis, bronchial asthma, or severs pneumonia;
- 4. Patients with uncontrolled active infections (bacteria, viruses or fungi infection) ;
- 5. Patients with acute and chronic GVHD (graft versus host disease)
- 6. Patients with severe autoimmune diseases;
Show all 10Show fewer
- 7. Previously treatment with T cell inhibitors (cyclophosphamide, FK506);
- 8. Patients with active hepatitis B or hepatitis C infection, HIV infection, syphilis serology reaction positive;
- 9. Patients who are participating or participated any other clinical research in the past 1 months;
- 10. Pregnant and/or lactating women will be excluded;
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
The Second People's Hospital of Shenzhen
Shenzhen, Guangdong
geng tian, 13724395569, tiangeng666@aliyun.com
About this study
Official title: Phase I/II Study of EGFR CART Cells for Patients With Metastatic Colorectal Cancer.
This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor EGFR (EGFR CART) cells in metastatic patients with colorectal cancer.
Read the detailed description
This is a study for the patients with colorectal cancer. Maximum tolerated dose climbing test is expected into the group of 9 cases of patients. And Phase II expected into the group of 11 subjects, selected the above safe dose, carrying out a research into the clinical effectiveness. Subjects will be collected their T cells and modify them, the modification is a genetic change, that EGFR:4-1BB:CD28:CD3 modified T cells, in order to tells the T cells to recognize their target tumor cells and potentially kill them, but not other normal cells in the subject's body. The CART cells will then be expanded in vitro and then administered to subjects. The purpose of this study is observe the MTD and to assess the safety and feasibility of CART cells in the patients with metastatic colorectal cancer.
- Conditions
- EGFR-positive Colorectal Cancer
- Being tested
- EGFR CART
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EGFR CARTBiological
EGFR CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%).
| Study group | Role | What they receive |
|---|---|---|
| anti-tumor response of CART-EGFR | Experimental | Not described Receives: Biological: EGFR CART |
What is being measured
The primary outcome is the main question the study is designed to answer.
Occurrence of study related adverse events as assessed by CTCAE v4.0
Measured: 24 weeks
Secondary outcomes (2)
Anti-tumor responses to EGFR CART cells in vivo.
Measured: 24 weeks
Determine duration of in vivo survival of EGFR CART .
EGFR CART vector sequences will be determined by Q-PCR
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 May 2017
- Study start15 Jun 2017
- Primary completionSep 2019 (estimated)
- Study completionDec 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EGFR-positive Colorectal CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shenzhen Second People's Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- The Beijing Pregene Science and Technology Company, Ltd.
- Responsible party
- Sponsor
- Investigators
- geng tian, Principal investigator, Shenzhen Second People's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03152435
- Sponsor's protocol ID
- FirstShenzhen02
- Status last verified
- May 2017
- First submitted
- 7 May 2017
- Last updated
- 16 Aug 2017
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Aug 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase I/II Study of EGFR CART Cells for Patients With Metastatic Colorectal Cancer.
- ClinicalTrials.gov ID
- NCT03152435
- Acronym / sponsor ID
- FirstShenzhen02
- Conditions
- EGFR-positive Colorectal Cancer
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Shenzhen Second People's HospitalUniversity, hospital or other
- Collaborators
- The Beijing Pregene Science and Technology Company, Ltd.
- Study start
- 15 Jun 2017 (actual)
- Primary completion
- Sep 2019 (estimated)
- Study completion
- Dec 2019 (estimated)
- First posted
- 15 May 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor EGFR (EGFR CART) cells in metastatic patients with colorectal cancer.
Detailed description
This is a study for the patients with colorectal cancer. Maximum tolerated dose climbing test is expected into the group of 9 cases of patients. And Phase II expected into the group of 11 subjects, selected the above safe dose, carrying out a research into the clinical effectiveness. Subjects will be collected their T cells and modify them, the modification is a genetic change, that EGFR:4-1BB:CD28:CD3 modified T cells, in order to tells the T cells to recognize their target tumor cells and potentially kill them, but not other normal cells in the subject's body. The CART cells will then be expanded in vitro and then administered to subjects. The purpose of this study is observe the MTD and to assess the safety and feasibility of CART cells in the patients with metastatic colorectal cancer.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| anti-tumor response of CART-EGFR | Experimental | Biological: EGFR CART |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- 1. Patients must be 18 years to 70 years;
- 2. Clinical diagnosis of EGFR positive for patients with metastatic colorectal cancer;
- 3. Patients must have a KPS of >80, expected survival > 3 months;
- 4. Patients must have at least one measurable lesions;
- 5. Recently did not use glucocorticoid;
Key exclusion criteria (10 listed)
- 1. Patients with other cancer history;
- 2. Patients allergic to cetuximab;
- 3. Patients with severe bronchitis, bronchial asthma, or severs pneumonia;
- 4. Patients with uncontrolled active infections (bacteria, viruses or fungi infection) ;
- 5. Patients with acute and chronic GVHD (graft versus host disease)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EGFR CARTEGFR CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%). | Biological | anti-tumor response of CART-EGFR |
Primary outcome
Occurrence of study related adverse events as assessed by CTCAE v4.0
Time frame: 24 weeks
2 secondary outcomes
Anti-tumor responses to EGFR CART cells in vivo.
Time frame: 24 weeks
Determine duration of in vivo survival of EGFR CART .
Time frame: 1 year
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Aug 2017.
Related trials for EGFR-positive Colorectal Cancer
RecruitingPhase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
HER2 Mutation-Related Tumors, HER2
RecruitingPhase 1
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Bladder Cancer, Head and Neck Squamous Cell Carcinoma
Not yet recruitingPhase 2
Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer
HER2 Positive, Colorectal Cancer (CRC)
RecruitingPhase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Solid Tumors, Advanced Cancer
Active, not recruitingPhase 2
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
MSI-H Colorectal Cancer, Melanoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
geng tian principal investigator
Shenzhen Second People's Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing EGFR CART in people with EGFR-positive Colorectal Cancer, run by Shenzhen Second People's Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 16 Aug 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact geng tian (13724395569, tiangeng666@aliyun.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Occurrence of study related adverse events as assessed by CTCAE v4.0 (time frame: 24 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Aug 2017.